Close Menu

IPO

The story has been corrected to state that Roka's technology is based on transcription mediated amplification methods, not PCR technology.

NEW YORK (GenomeWeb) – CareDx expects to price the shares in its proposed initial public offering at between $15 and $17 per share, with net proceeds anticipated at up to $50.5 million.

NEW YORK (GenomeWeb) – Molecular diagnostics firm T2 Biosystems has filed for an initial public offering, seeking to raise as much as $69 million in proceeds.

NEW YORK (GenomeWeb) – Microlin Bio is pushing ahead with its bid to go public on the Nasdaq, disclosing last week that it now expects to float roughly 4.3 million shares for between $6.50 and $7.50 apiece, which would raise as much as $32.3 million for the microRNA therapeutics and diagnostics s

NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics has priced its initial public offering at $10 per share with gross proceeds expected at $8.5 million.

NEW YORK (GenomeWeb) – Signal Genetics raised the target amount from its proposed initial public offering to up to $12.1 million.

NEW YORK (GenomeWeb) – Foodborne pathogen molecular diagnostics firm Roka Bioscience has filed with the US Securities and Exchange Commission to go public.

NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics lowered the amount it intends to raise from its proposed initial public offering to $9.3 million from a previous target of $25 million, it said in an amended preliminary prospectus filed with the US Securities and Exchange Commission

NEW YORK (GenomeWeb) – Melanoma test development firm DermTech International has filed to go public with a proposed offering of up to $25 million in stock.

NEW YORK (GenomeWeb) – Ariosa Diagnostics has priced its planned initial public offering of 3.5 million shares.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.